Abstract
Carboplatin and interferon β (IFN β) were tested alone and in combination for their anti-proliferative activity on the human melanoma cell line SK-MEL 28 in vitro. Cells were incubated for 4 days in the presence of carboplatin (0.1 mM and 0.1 μM) and interferon β (5 pM and 5 nM) and cell growth inhibition was determined by the sulphorhodamin B assay. The antiproliferative effects of the drug combinations were analysed using Berenbaum's hyperplane theorem to determine additive, synergistic and antagonistic effects. IFNβ was found to be 10 000 times more active in inhibiting cell growth of SK-MEL 28 cells than carboplatin on the basis of IC50 values (IFNβ: IC50=1.24 nM, carboplatin: IC50=18.2, μM). The addition of IFN β at 0.5 nM reduced the IC50 value of carboplatin 18.0-fold; with IFN β at 0.05 nM a dose reduction of 1.84 was measured. At the carboplatin: IFNβ molar concentration ratios of 2000:1 and 6000:1, interaction indices (I) of 0.66 and 0.83 were determined respectively, indicating synergistic interactions between the two drugs. At higher carboplatin: IFNβ molar ratios (20 000:1 and 60 000:1) an additive interaction was observed (I=1.07 and 1.20). However, further in vitro studies with serveral melanoma cell lines are necessary to evaluate the potential effectiveness of the drug combination of carboplatin and IFNβ for eventual clinical utilisation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aapro MS, Alberts DS, Salmon SE (1983) Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay. Cancer Chemother Pharmacol 10:161–166
Berenbaum MC (1989) What is synergy? Pharmacol Rev 41:93
Cho YL, Christensen C, Saunders DE, Lawrence WD, Deppe G, Malviya VK, Malone JM (1991) Combined effects of 1,25-dihydroxyvitamin D3 and platinum drugs on the growth of MCF-7 cells Cancer Res 51:2848–2853
Evans LM, Casper ES, Rosenbluth R (1987) Phase II trail of carboplatin in advanced malignant melanoma. Cancer Treat Rep 71:173–174
Garbe C Krasagakis K, Zouboulis CC, Schröder K, Stadler R, Orfanos CE (1990) Antitumor activities of interferon alpha, beta and gamma and their combinations on human melanoma cells in vitro. J Invest Dermatol 95:231S-237S
Garbe C, Krasagakis K, Zouboulis CC, Krüger S, Waibel M, Kreuser ED, Stadler R, Orfanos CE (1992) Kombination von Interferon-α mit Zytostatika: erfolgversperchender Therapieasatz beim metastasierendem Melanom. Hautarzt 43:4–10
Hassan HT, Maurer HR (1992) Synergism between interferon-alpha and carboplatin in inhibiting K562 human myeloid leukemia clonogenic cells: new potential therapeutic development. Leuk Res 16:419–420
Hassan HT, Veit A, Maurer HR (1991) Synergistic interactions between differentiation-inducing agents in inhibiting the proliferation of HL-60 human myeloid leukemia cells in clonogenic micro assays. J Cancer Res Clin Oncol 117:227–231
Ito M, Hayashi Y, Tanabe F, Shigeta S, Kawade Y (1987) Synergistic antiproliferative effect of interferon β in combination with bleomycin or neocarzinostatin on Hela cells in culture:additive effect when combined with Adriamycin or mitomycin. J Interferon Res 7:419–425
Johns TG, Mackay IR, Callister KA, Hertzog PJ, Devenish RJ, Linnane AW (1992) Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon β. J Natl Cancer Inst 84:1185–1190
Kano Y, Akutsu M, Suzuki K, Yoshida M (1993) Effects of carboplatin in combination with other anticancer agents on human leukemia cell lines. Leuk Res 17:113–119
Karakousis CP, Getez EP, Bjornsson S (1979)cis-Dichloro-diammineplatinum(II) and DTIC in malignant melanoma. Cancer Treat Rep 63:2009–2010
Otto AM (1994) Combinations of interferon with platinum complexes: synergistic and antagonistic effects on growth inhibition of MCF-7 and MDA-MB 231 breast cancer cells. J Cancer Res Clin Oncol 120:286–292
Pfeffer LA (1987) Cellular effects of interferons vol 2. In: Pfeffer LA (ed) Mechanism of interferon action CRC, Boca Raton, Fla. pp 2–23
Salmon SE, Durie GM, Young L, Liu RM, Trown PW, Stebbing N (1983) Effects of cloned human leukocyte interferons in the human tumor stem cell assay. J Clin Oncol 1:217–225
Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Viszica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107–1112
Wadler S, Schwartz EL (1990) Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies. A review Cancer Res 50:3473–3486
Welander CE, Morgan TM, Homesley HD, Trotta PP, Spiegel RJ (1985) Combined recombinant human interferon β2 and cytotoxic agents in a clonogenic assay. Int J Cancer 35:721–725
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hübner, B., Eckert, K., Garbe, C. et al. Synergistic interactions between interferonβ and carboplatin on SK-MEL 28 human melanoma cell growth inhibition in vitro. J Cancer Res Clin Oncol 121, 84–88 (1995). https://doi.org/10.1007/BF01202218
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01202218